{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:20:00Z","timestamp":1788546000638,"version":"build-2803163510"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"Importance<\/jats:title>The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the noninferiority of SII-NVX-CoV2373 in children and adolescents compared to adults and to evaluate its safety in comparison with placebo.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This phase 2-3 observer-blind randomized clinical trial was conducted in 2 cohorts, children (aged 2 to 11 years) and adolescents (aged 12 to 17 years) between August 2021 and August 2022. Participants were randomized 3:1 to SII-NVX-CoV2373 or placebo and monitored for 179 days. The participants, study team, and laboratory staff were blinded. This was a multicenter study conducted across 10 tertiary care hospitals in India. Exclusion criteria included previous COVID-19 infection or vaccination, immunocompromised condition, and immunosuppressive medications.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Two doses of 0.5-mL SII-NVX-CoV2373 or placebo were administered intramuscularly on days 1 and 22.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes were geometric mean titer ratio of both anti-spike (anti-S) IgG and neutralizing antibodies (NAbs) between both pediatric age groups to that of adults on day 36. Noninferiority was concluded if the lower bound of 95% CI of this ratio was greater than 0.67 for each age group. Both the antibodies were assessed for the index strain and for selected variants at various time points. Solicited adverse events (AEs) were recorded for 7 days after each vaccination, unsolicited AEs were recorded for 35 days, and serious AEs and AEs of special interest were recorded for 179 days.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 460 children in each age cohort were randomized to receive vaccine or placebo. The mean (SD) age was 6.7 (2.7) years in the child cohort and 14.3 (1.6) years in the adolescent cohort; 231 participants (50.2%) in the child cohort and 218 in the adolescent cohort (47.4%) were female. Both anti-S IgG and NAb titers were markedly higher in the SII-NVX-CoV2373 group than in the placebo group on both day 36 and day 180. The geometric mean titer ratios compared to those in adults were 1.20 (95% CI, 1.08-1.34) and 1.52 (95% CI, 1.38-1.67) for anti-S IgG in adolescents and children, respectively; while for NAbs, they were 1.33 (95% CI, 1.17-1.50) and 1.93 (95% CI, 1.70-2.18) in adolescents and children, respectively, indicating noninferiority. SII-NVX-CoV2373 also showed immune responses against variants studied. Injection site reactions, fever, headache, malaise, and fatigue were common solicited AEs. There were no AEs of special interest and no causally related serious AEs.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>SII-NVX-CoV2373 was safe and well tolerated in children and adolescents in this study. The vaccine was highly immunogenic and may be used in pediatric vaccination against COVID-19.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Clinical Trials Registry of India Identifier: CTRI\/2021\/02\/031554<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2023.2552","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T15:33:11Z","timestamp":1690817591000},"page":"911","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India"],"prefix":"10.1001","volume":"177","author":[{"given":"Bhagwat","family":"Gunale","sequence":"first","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay","family":"Kapse","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kar","sequence":"additional","affiliation":[{"name":"Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bavdekar","sequence":"additional","affiliation":[{"name":"King Edward Memorial Hospital Research Centre, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kohli","sequence":"additional","affiliation":[{"name":"Hamdard Institute of Medical Sciences and Research With Centre for Health Research and Development, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Lalwani","sequence":"additional","affiliation":[{"name":"Bharati Vidyapeeth Deemed University Medical College and Hospital, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Meshram","sequence":"additional","affiliation":[{"name":"Super Speciality Hospital, Government Medical College and Hospital, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Raut","sequence":"additional","affiliation":[{"name":"Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Wardha, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"JSS Academy of Higher Education and Research, Mysore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence","family":"Samuel","sequence":"additional","affiliation":[{"name":"Christian Medical College & Hospital, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Munshi","sequence":"additional","affiliation":[{"name":"Topiwala National Medical College and Bai Yamunabai Laxman Nair Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce S.","family":"Plested","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Cloney-Clark","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingZhu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Pryor","sequence":"additional","affiliation":[{"name":"360biolabs, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hamilton","sequence":"additional","affiliation":[{"name":"360biolabs, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Thakar","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research, National AIDS Research Institute, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Shete","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research, National AIDS Research Institute, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Dharmadhikari","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetanraj","family":"Bhamare","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Shaligram","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus S.","family":"Poonawalla","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raburn M.","family":"Mallory","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Glenn","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Serum Institute of India, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COVOVAX-Ped study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod C","family":"Samantaray","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Kawade","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunkumar","family":"Gondhali","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Jain","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Goyal","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Arya","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temsunaro","family":"Rongsen-Chandola","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Palkar","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta M","family":"Hanumante","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj H","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna A","family":"Shyamkuwar","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B S","family":"Garg","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Meshram","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayshri","family":"Deotale","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Mahajan","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Kalantri","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwala H","family":"V","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi V","family":"Rao","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Kamra","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Singh","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Kumbhar","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrakshi","family":"Sharma","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Choche","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Ghatage","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugam","family":"Salvi","sequence":"additional","affiliation":[{"name":"for the COVOVAX-Ped study group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"40","key":"poi230043r1","doi-asserted-by":"publisher","first-page":"24620","DOI":"10.1073\/pnas.2012358117","article-title":"Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics.","volume":"117","author":"Steinman","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"poi230043r2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-020-0962-9","article-title":"Age-dependent effects in the transmission and control of COVID-19 epidemics.","volume":"26","author":"Davies","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"poi230043r3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2352-4642(21)00198-X","article-title":"Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.","volume":"5","author":"Molteni","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"poi230043r4","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-4642(21)00066-3","article-title":"Children and young people remain at low risk of COVID-19 mortality.","volume":"5","author":"Bhopal","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"poi230043r5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41591-021-01578-1","article-title":"Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year.","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"poi230043r6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40272-020-00435-x","article-title":"Multisystem inflammatory syndrome in children related to SARS-CoV-2.","volume":"23","author":"Esposito","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"3","key":"poi230043r7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jama.2021.23262","article-title":"Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France.","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"poi230043r8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.15585\/mmwr.mm7102e1","article-title":"Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12\u201318 years\u2014United States, July\u2013December 2021.","volume":"71","author":"Zambrano","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"poi230043r9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15585\/mmwr.mm7102e2","article-title":"Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years\u2014United States, March 1, 2020-June 28, 2021.","volume":"71","author":"Barrett","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"poi230043r10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamapediatrics.2021.2770","article-title":"Association of age and pediatric household transmission of SARS-CoV-2 infection.","volume":"175","author":"Paul","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"13","key":"poi230043r16","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine.","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"poi230043r17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico.","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"poi230043r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9135","article-title":"Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial.","volume":"6","author":"Anez","year":"2023","journal-title":"JAMA Netw Open"},{"key":"poi230043r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2022.100139","article-title":"Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2\/3, observer-blind, randomised, controlled study.","volume":"10","author":"Kulkarni","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"3","key":"poi230043r25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data.","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"issue":"3","key":"poi230043r26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents.","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"poi230043r27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age.","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"poi230043r28","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents.","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"poi230043r29","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"poi230043r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10780","article-title":"Assessment of neutralizing antibody response against SARS-CoV-2 variants after 2 to 3 doses of the BNT162b2 mRNA COVID-19 vaccine.","volume":"5","author":"Furukawa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"poi230043r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003991","article-title":"Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study.","volume":"19","author":"van Gils","year":"2022","journal-title":"PLoS Med"},{"issue":"1","key":"poi230043r33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41467-023-37176-7","article-title":"Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.","volume":"14","author":"Cromer","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"poi230043r34","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.4103\/jfmpc.jfmpc_2274_21","article-title":"Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: an interim result from a large multicentric population-based seroepidemiological study.","volume":"11","author":"Misra","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"poi230043r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100338","article-title":"Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: a population-based serosurvey.","volume":"15","author":"Coelho","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"11","key":"poi230043r36","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"poi230043r37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S0022172400062410","article-title":"Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.","volume":"95","author":"Callow","year":"1985","journal-title":"J Hyg (Lond)"},{"issue":"5","key":"poi230043r39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/CIRCULATIONAHA.121.056583","article-title":"Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination.","volume":"145","author":"Truong","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"poi230043r40","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cjca.2021.08.001","article-title":"Myocarditis and pericarditis after COVID-19 mRNA vaccination: practical considerations for care providers.","volume":"37","author":"Luk","year":"2021","journal-title":"Can J Cardiol"},{"issue":"7","key":"poi230043r41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004056","article-title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study.","volume":"19","author":"Massari","year":"2022","journal-title":"PLoS Med"},{"issue":"31","key":"poi230043r42","doi-asserted-by":"publisher","first-page":"988","DOI":"10.15585\/mmwr.mm7131a2","article-title":"Interim recommendation of the advisory committee on immunization practices for use of the Novavax COVID-19 Vaccine in Persons Aged =18 years\u2014United States, July 2022.","volume":"71","author":"Twentyman","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"poi230043r43","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1186\/s12889-021-11725-5","article-title":"Parental COVID-19 vaccine hesitancy for children: vulnerability in an urban hotspot.","volume":"21","author":"Alfieri","year":"2021","journal-title":"BMC Public Health"},{"key":"poi230043r44","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.844310","article-title":"Determinants of COVID-19 vaccine uptake in adolescents 12-17 years old: examining pediatric vaccine hesitancy among racially diverse parents in the United States.","volume":"10","author":"Gray","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"poi230043r45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/vaccines10010031","article-title":"COVID-19 pediatric vaccine hesitancy among racially diverse parents in the United States.","volume":"10","author":"Fisher","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"poi230043r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107125","article-title":"Parents\u2019 perceptions on COVID-19 vaccination as the new routine for their children =11 years old.","volume":"161","author":"Humble","year":"2022","journal-title":"Prev Med"},{"issue":"26","key":"poi230043r47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.15585\/mmwr.mm7126a3","article-title":"COVID-19 vaccine provider availability and vaccination coverage among children aged 5-11 years\u2014United States, November 1, 2021-April 25, 2022.","volume":"71","author":"DeCuir","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"poi230043r48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.puhe.2022.02.002","article-title":"Public attitudes and influencing factors toward COVID-19 vaccination for adolescents\/children: a scoping review.","volume":"205","author":"Liu","year":"2022","journal-title":"Public Health"},{"issue":"11","key":"poi230043r49","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1097\/TP.0000000000003922","article-title":"Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients.","volume":"105","author":"Haskin","year":"2021","journal-title":"Transplantation"},{"issue":"30","key":"poi230043r50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/pedi.v22.S30","article-title":"Safety and immunogenicity of the BNT162B2 MRNA vaccine for COVID-19 in adolescents and young adults with type 1 diabetes.","volume":"22","author":"Macedoni","year":"2021","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"poi230043r51","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00467-021-05256-9","article-title":"Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients.","volume":"37","author":"Crane","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"poi230043r52","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v68.12","article-title":"COVID-19 vaccination in pediatric cancer patients: a high priority.","volume":"68","author":"Charla","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"49","key":"poi230043r53","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1016\/j.vaccine.2022.10.045","article-title":"Safety, tolerability and immunogenicity of Biological E\u2019s CORBEVAX vaccine in children and adolescents: a prospective, randomised, double-blind, placebo controlled, phase-2\/3 study.","volume":"40","author":"Thuluva","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"poi230043r54","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1473-3099(22)00307-3","article-title":"Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2\/3 study.","volume":"22","author":"Vadrevu","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"poi230043r11","unstructured":"About COVID-19 vaccination. National Health Service. Accessed August 12, 2022. https:\/\/www.nhs.uk\/conditions\/coronavirus-covid-19\/coronavirus-vaccination\/coronavirus-covid-19-vaccination-for-children\/coronavirus-covid-19-vaccine-for-children-aged-5-to-15\/"},{"key":"poi230043r12","unstructured":"COVID-19 Vaccines for Children and Teens. US Centers for Disease Control and Prevention. Accessed January 12, 2023. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/children-teens.html"},{"key":"poi230043r13","unstructured":"NTAGI panel recommends use of COVID vaccines Corbevax, Covaxin for kids aged 5-12 years. The Indian Express. Accessed August 12, 2022. https:\/\/indianexpress.com\/article\/india\/ntagi-panel-recommends-use-of-covid-vaccines-corbevax-covaxin-for-kids-aged-5-12-years-8017862\/"},{"key":"poi230043r14","unstructured":"Guidelines for COVID-19 vaccination of children between 12-14 years of age. Ministry of Health and Family Welfare. Accessed January 13, 2023. https:\/\/www.mohfw.gov.in\/pdf\/GuidelinesCovidvaccination12to14yrchildrenMarch2022.pdf"},{"key":"poi230043r15","unstructured":"Co-WIN. Accessed January 13, 2023. Ministry of Health and Family Welfare. https:\/\/dashboard.cowin.gov.in\/"},{"key":"poi230043r20","unstructured":"Panel recommends EUA for COVID-19 vaccines Covovax, Corbevax and anti-COVID pill Molnupiravir. The Hindu. Accessed August 12, 2022. https:\/\/www.thehindu.com\/news\/national\/cdsco-panel-recommends-restricted-emergency-use-of-anti-covid-pill-molnupiravir\/article38051321.ece"},{"key":"poi230043r21","unstructured":"WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. World Health Organization. Accessed on August 12, 2022. https:\/\/www.who.int\/news\/item\/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries#:~:text=lower%2Dincome%20countries-,WHO%20lists%209th%20COVID%2D19%20vaccine%20for%20emergency%20use%20with,vaccination%20in%20lower%2Dincome%20countries&text=Today%2C%20the%20World%20Health%20Organization,SARS%2DCoV%2D2%20virus"},{"key":"poi230043r22","unstructured":"NTAGI approves Serum's Covovax COVID-19 vaccine for 12-17 age group: report. Business Today. Accessed January 13, 2023. https:\/\/www.businesstoday.in\/coronavirus\/story\/ntagi-approves-serums-covovax-covid-19-vaccine-for-12-17-age-group-report-331844-2022-04-29"},{"key":"poi230043r23","unstructured":"Back govt panel approves Covovax vaccine for 7-11-year-olds. explainer. Mint. Accessed January 13, 2023. https:\/\/www.livemint.com\/news\/india\/govt-panel-approves-covovax-vaccine-for-7-11-year-olds-explainer-11656116891572.html"},{"key":"poi230043r24","unstructured":"Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series 1004, Annex 9, 2017. World Health Organization (WHO). Published October 21, 2020. Accessed December 3, 2022. https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9"},{"key":"poi230043r30","unstructured":"COVID-19 cases and deaths. World Health Organization. November 28, 2022. https:\/\/app.powerbi.com\/view?r=eyJrIjoiYWRiZWVkNWUtNmM0Ni00MDAwLTljYWMtN2EwNTM3YjQzYmRmIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9"},{"key":"poi230043r38","unstructured":"Shimabukuro? T. COVID-19 vaccine safety updates: Vaccines and Related Biological Products Advisory Committee (VRBPAC). US Food and Drug Administration. Published June 10, 2021. Accessed July 4, 2021. https:\/\/www.fda.gov\/media\/150054\/download"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2807909\/jamapediatrics_gunale_2023_oi_230043_1692993135.78049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:28:58Z","timestamp":1693927738000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2807909"}},"subtitle":["A Phase 2-3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2023.2552","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}